Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2.
Merchant M, Raygada M, Pang Y, Quezado M, Raffeld M, Xi L, Kim J, Tyagi M, Abdullaev Z, Kim O, Sergi Z, Pillai T, Ozer B, Zaghloul K, Heiss JD, Armstrong TS, Gilbert MR, Aldape K, Wu J. Merchant M, et al. Among authors: ozer b. Front Oncol. 2022 Aug 2;12:954879. doi: 10.3389/fonc.2022.954879. eCollection 2022. Front Oncol. 2022. PMID: 35982947 Free PMC article.
Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT).
Leeper HE, Tonorezos E, Mayer D, Bakitas M, Chang S, Cooley ME, Hervey-Jumper S, Miaskowski C, Sherwood P, Tsien C, Wallgren K, Willmarth N, Arons D, Acquaye A, King AL, Penas-Prado M, Vera E, Gilbert MR, Armstrong TS; NCI-CONNECT Survivorship Care in Neuro-Oncology Workshop. Leeper HE, et al. Neurooncol Adv. 2022 Feb 28;4(1):vdac029. doi: 10.1093/noajnl/vdac029. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35542753 Free PMC article. Review.
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.
Rogers JL, Wall T, Acquaye-Mallory AA, Boris L, Kim Y, Aldape K, Quezado MM, Butman JA, Smirniotopoulos JG, Chaudhry H, Tsien CI, Chittiboina P, Zaghloul K, Aboud O, Avgeropoulos NG, Burton EC, Cachia DM, Dixit KS, Drappatz J, Dunbar EM, Forsyth P, Komlodi-Pasztor E, Mandel J, Ozer BH, Lee EQ, Ranjan S, Lukas RV, Raygada M, Salacz ME, Smith-Cohn MA, Snyder J, Soldatos A, Theeler BJ, Widemann BC, Camphausen KA, Heiss JD, Armstrong TS, Gilbert MR, Penas-Prado M. Rogers JL, et al. Among authors: ozer bh. J Neurooncol. 2024 Apr;167(2):349-359. doi: 10.1007/s11060-024-04613-6. Epub 2024 Mar 1. J Neurooncol. 2024. PMID: 38427131 Free PMC article.
Safety of temozolomide use in adult patients with renal dysfunction.
Garzio K, McElroy K, Grossman S, Holdhoff M, Ozer B, Yankulina O. Garzio K, et al. Among authors: ozer b. J Neurooncol. 2022 Sep;159(3):591-596. doi: 10.1007/s11060-022-04098-1. Epub 2022 Aug 24. J Neurooncol. 2022. PMID: 36001203 Free PMC article.
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL, Rudneva VA, Richards AL, Zhang Y, Woo HJ, Cohen M, Tisnado J, Majd N, Wardlaw SL, Page-Wilson G, Sengupta S, Chow F, Goichot B, Ozer BH, Dietrich J, Nachtigall L, Desai A, Alano T, Ogilive S, Solit DB, Bale TA, Rosenblum M, Donoghue MTA, Geer EB, Tabar V. Lin AL, et al. Among authors: ozer bh. Acta Neuropathol. 2024 May 17;147(1):85. doi: 10.1007/s00401-024-02736-8. Acta Neuropathol. 2024. PMID: 38758238 Free PMC article.
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A. Nguyen HN, et al. Among authors: ozer b. Neuro Oncol. 2017 Mar 1;19(3):394-404. doi: 10.1093/neuonc/now189. Neuro Oncol. 2017. PMID: 27571882 Free PMC article.
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, Prins R, Nghiemphu PL, Yong W, Cloughesy T, Lai A. Liu F, et al. Among authors: ozer b. J Neurooncol. 2019 May;142(3):423-434. doi: 10.1007/s11060-019-03126-x. Epub 2019 Mar 5. J Neurooncol. 2019. PMID: 30838489 Free PMC article.
167 results